Florida Doc's DEA Dreams Dashed: No More Controlled Prescriptions Allowed
Published Date: 9/23/2025
Notice
Summary
Dr. Immacula Michel from Florida tried to get a DEA registration but didn’t follow the rules by prescribing controlled drugs without proper registration. Because she didn’t respond or ask for a hearing in time, her application was denied. This means she can’t legally prescribe controlled substances, and the decision is final as of September 2025.
Analyzed Economic Effects
2 provisions identified: 0 benefits, 2 costs, 0 mixed.
DEA Registration Denied for Dr. Michel
The DEA denied Immacula Michel, M.D.'s application for a Certificate of Registration (Control No. W23121768C). The denial also applies to any other pending registration application of Dr. Michel in Florida, and the Order is effective October 23, 2025. Without a DEA registration, she cannot lawfully dispense or prescribe controlled substances under federal law.
Default Finding: Three Unauthorized Prescriptions
The Agency found that, between November 2024 and February 2025, Dr. Michel issued three prescriptions for phentermine (a Schedule IV controlled substance) under a surrendered DEA registration, and because she did not timely request a hearing she is deemed in default and to have admitted those allegations. The record shows her prior DEA registration was surrendered on August 4, 2022.
Your PRIA Score
Personalized for You
How does this regulation affect your finances?
Sign up for a PRIA Policy Scan to see your personalized alignment score for this federal register document and every other regulation we track. We analyze your financial profile against policy provisions to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-10128 — Revision of Applications for Manufacturing and Procurement Quotas
The DEA wants to update how companies apply for permission to make and buy certain controlled drugs and chemicals. These changes will make the rules clearer, help prevent drug shortages, and ensure enough supply for medical and scientific needs. If you’re a manufacturer or involved in this process, get ready to follow new steps and share your thoughts by July 20, 2026.
2026-10253 — Schedules of Controlled Substances: Temporary Placement of 2-Fluorodeschloroketamine in Schedule I
Starting May 22, 2026, the DEA is putting 2-fluorodeschloroketamine (2-FDCK) into Schedule I, meaning it’s now treated like the most dangerous drugs. This affects anyone who makes, sells, or uses it, adding strict rules and serious penalties. The temporary ban lasts two years, giving the government time to decide if it should stay permanent.
2026-10090 — Exempt Chemical Preparations Under the Controlled Substances Act
The Drug Enforcement Administration (DEA) reviewed and decided on applications for special chemical mixtures that don’t fall under strict drug rules, covering requests from July 2025 to March 2026. Some mixtures got approved, others denied, and a few listings were fixed from earlier notices. If you’re involved with these chemicals, you’ve got until July 20, 2026, to share your thoughts—no fees or big costs involved, just your voice!
2026-09566 — Schedules of Controlled Substances: Placement of CUMYL-PEGACLONE in Schedule I
Starting May 13, 2026, the DEA officially puts CUMYL-PEGACLONE—a chemical that can be risky—into Schedule I, the strictest drug category. This means anyone making, selling, or using it now faces tough rules and penalties. This move helps the U.S. follow international drug laws and keeps communities safer without any new fees or costs.
2026-08587 — Importer of Controlled Substances Application: ANI Pharmaceuticals Inc.
ANI Pharmaceuticals wants to import certain controlled drugs like Levorphanol and Tapentadol. People who make or use these drugs can share their thoughts or ask for a hearing by June 3, 2026. This move could affect drug availability and regulation, so keep an eye on the deadline to have your say!
2026-08588 — Bulk Manufacturer of Controlled Substances Application: Patheon API Inc.
Patheon API Inc. wants to make large amounts of special research drugs like dimethyltryptamine and psilocybin. This affects researchers and companies involved in clinical trials, with a chance to comment or ask for a hearing by July 6, 2026. No money changes are mentioned, but this move could speed up important medical studies.
Previous / Next Documents
Previous: 2025-18360 — Presence Sensing Device Initiation (PSDI) Standard; Extension of the Office of Management and Budget's (OMB) Approval of Information Collection (Paperwork) Requirements
OSHA is asking for public feedback as it seeks to keep the approval for collecting info under the Presence Sensing Device Initiation (PSDI) Standard. This mainly affects businesses using safety sensors on machines to protect workers. No big changes or extra costs are expected, but the approval needs to be renewed to keep things running smoothly.
Next: 2025-18362 — Rachel Kientcha-Tita, M.D.; Decision and Order
Dr. Rachel Kientcha-Tita from Houston lost her DEA registration because she’s barred from Medicare, Medicaid, and other federal health programs. The DEA officially revoked her license and denied her renewal after a thorough review and hearing. This means she can’t legally prescribe controlled substances through federal programs anymore, effective immediately.